Dexamethasone and Lower Extremity Block Duration

This study is not yet open for participant recruitment.
Verified December 2012 by University of Chicago
Sponsor:
Information provided by (Responsible Party):
Tariq Malik, University of Chicago
ClinicalTrials.gov Identifier:
NCT01756586
First received: December 20, 2012
Last updated: NA
Last verified: December 2012
History: No changes posted
  Purpose

Dexamethasone has shown to prolong upper extremity blocks. No one ha studied its effect on lower extremity blocks. The study would evaluate that point.


Condition Intervention
Analgesia Duration
Drug: Dexamethasone

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • increase in the duration of block [ Time Frame: one year ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: February 2013
Estimated Study Completion Date: December 2013
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Control
Plain bupivacaine
Experimental: Experimental
Bupivacaine with Dexamethasone
Drug: Dexamethasone

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age 18-75
  2. foot surgery
  3. no contraindication to regional anesthesia

Exclusion Criteria:

  1. opioid dependent
  2. chronic pain condition
  3. peripheral neuropathy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01756586

Contacts
Contact: Tariq Malik, MD 773-834-3139 tmalik@dacc.uchicago.edu
Contact: Tariq Malik 773-834 3646 tmalik@dacc.uchicago.edu

Locations
United States, Illinois
University of Chicago Medical Center Not yet recruiting
Chicago, Illinois, United States, 60637
Contact: Tariq Malik     773-834-3643     tmalik@dacc.uchicago.edu    
Contact: Tariq Malik         tmalik@dacc.uchicago.edu    
Principal Investigator: Tariq Malik, MD            
Sponsors and Collaborators
University of Chicago
  More Information

No publications provided

Responsible Party: Tariq Malik, Assistant Professor, University of Chicago
ClinicalTrials.gov Identifier: NCT01756586     History of Changes
Other Study ID Numbers: IRB12-2198
Study First Received: December 20, 2012
Last Updated: December 20, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Chicago:
popliteal block
analgesia duration

Additional relevant MeSH terms:
Dexamethasone acetate
Dexamethasone
Dexamethasone 21-phosphate
BB 1101
Anti-Inflammatory Agents
Therapeutic Uses
Pharmacologic Actions
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Central Nervous System Agents
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 22, 2013